http://www.renub.com/report/hepatitis-c-market-forecast-hcv-drugs-clinical-trials-hepatitis-c-pipeline-drugs-sales-forecast---worldwide-118 Renub Research has announced the addition of the "Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” report to its offering Click here to view the report details: http://www.renub.com/report/hepatitis-c-market-forecast-hcv-drugs-clinical-trials-hepatitis-c-pipeline-drugs-sales-forecast---worldwide-118 Contact Us Andy Hill Sr. Manager - Publisher Relation Sales & Marketing Div. Renub Research Email: info@renub.com Phone: +1-678-302-0700 (USA) , +91-120-4219-822, +91-120-254-5750 (India) Web: http://www.renub.com/ About US: Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.

1. Hepatitis C Market & Forecast, HCV Drugs
Clinical Trials, Hepatitis C Pipeline Drugs Sales
& Forecast - Worldwide
Renub Research
www.renub.com
Published: July, 2013
Copyright © 2013 Renub Research – All Rights Reserved
From Data to Analysis
Hepatitis C Market
Research Report

2. Hepatitis C Market Overview
Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size
of 2012. Hepatitis C virus (HCV) infection is a complex public health problem, characterized by
a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low
rates of testing, treatment and the prospect of increasing incidence associated with the
epidemic of injection drug use. Hepatitis C is a leading cause of chronic liver disease, end-
stage cirrhosis and liver cancer. Because of the slow progression and asymptomatic character
of the infection, many people are unaware of having it. As a consequence, the infection is
often diagnosed at a late stage when treatment options are limited. As no effective vaccine
against the Hepatitis C virus (HCV) has been discovered so far the market is driven by
therapeutics. The increase in the prevalence of the disease and the availability of new first-in-
class therapies with better safety and efficacy profiles are expected to drive the growth of the
HCV market. The growth in HCV drugs market is primarily attributed to high unmet need in the
market which is expected to be fulfilled by strong pipeline candidates. Low levels of awareness
and knowledge about HCV have been identified as a formidable challenge to prevention and
care.
Renub Research study titled “Hepatitis C Drug Market & Forecast, HCV Drugs Clinical Trials,
Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” provides a comprehensive
assessment of the fast-evolving, high-growth of Hepatitis sector. This 164 page report with 25
Figures and 2 Tables studies the Hepatitis C Drug Market Landscape. This report contains 7
chapters.
A. Hepatitis C Drugs Market & Forecast (Chapter 2)
B. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
C. Hepatitis C Deals & Acquisitions (Chapter 4)
D. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter 5)
E. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter 6)
F. Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)
Hepatitis C – Approved Drugs sales & Forecast Analysis (To 2016) (Chapter No. 3)
1. Pegasys
2. Pegintron
3. Incivek
4. Victrelis
© Renub Research Page 2 of 12

3. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter No. 5)
1. Simeprevir (TMC 435) (Company: Janssen Pharmaceutical)
2. Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim)
3. Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb)
4. PEG-Interferon Lambda (Company: Bristol-Myers Squibb)
5. Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)
6. Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb)
7. BI-207127 (Company: Boerhinger Ingelheim)
8. ABT-450/r (Ritonavir) (Company: Abbott Laboratories)
9. ABT-267 (Company: Abbott Laboratories)
10.ABT-072/333 (Company: Abbott Laboratories)
11.Alisporivir (Company: Novartis)
Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter No. 6)
1. Mericitabine (RG-7128) (Company: Roche)
2. Danoprevir/r (Ritonavir) (RG7227) (Company: Roche)
3. GS-9256 (Company: Gilead Sciences)
4. GS-9451 (Company: Gilead Sciences)
5. MK-5172 (Company: Merck)
6. Sovaprevir (ACH-1625) (Company: Achillion)
7. IDX-320 (Company: Idenix)
8. MK-8742 (Company: Merck)
9. ACH-3102 (Company: Achillion Pharmaceuticals, Inc)
10.IDX-719 (Company: Idenix)
11.PPI-668 (Company: Presidio Pharmaceuticals)
12.Setrobuvir (ANA-598) (Company: Roche)
13.VX-222 (Company: Vertex Pharmaceuticals)
14.GS-9669 (Company: Gilead Sciences)
15.GS-9190 (Tegobuvir) (Company: Gilead Sciences)
16.BMS-791325 (Company: Bristol-Myers Squibb)

4. Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)
1. Simeprevir (TMC 435)
2. Faldaprevir (BI 201335) (Boerhinger
Ingelheim)
3. Asunaprevir (BMS-650032)
4. Sofosbuvir (PSI-7977 or GS-7977)
5. Daclatasvir (BMS-790052)
6. ABT-450/r (Ritonavir)
7. ABT-072/333
8. Alisporivir
9. Mericitabine (RG-7128)
10.Danoprevir (RG7227)
11.GS-9256
12.Setrobuvir (ANA-598)
13.VX-222
14.GS-9190 (Tegobuvir)
15.BMS-791325
Data Sources
This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non-
printable sources like search engines, News websites, Government Websites, Trade Journals,
White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books,
Industry Portals, Industry Associations and access to more than 500 paid databases.
© Renub Research Page 4 of 12

5. Table of Contents
1. Executive Summary
2. Hepatitis C Drugs – Market & Forecast
3. Hepatitis C – Approved Drugs Sales & Forecast
3.1 Pegasys Sales and Forecast
3.2 Pegintron Sales and Forecast
3.3 Incivek Sales and Forecast
3.4 Victrelis Sales and Forecast
4. Hepatitis C – Deals & Acquisitions
5. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III)
5.1 Simeprevir (TMC 435) (Company: Janssen Pharmaceutical)
5.1.1 Phase I
5.1.2 Phase II
5.1.3 Phase III
5.2 Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim)
5.2.1 Phase I
5.2.2 Phase II
5.2.3 Phase III
5.3 Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb)
5.3.1 Phase I
5.3.2 Phase II
5.3.3 Phase III
5.4 Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)
© Renub Research Page 5 of 12

6. 5.4.1 Phase II
5.4.2 Phase III
5.5 Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb)
5.5.1 Phase II
5.5.2 Phase III
5.6 BI-207127 (Company: Boerhinger Ingelheim)
5.6.1 Phase I
5.6.2 Phase II
5.6.3 Phase III
5.7 PEG-Interferon Lambda (Company: Bristol-Myers Squibb)
5.7.1 Phase I
5.7.2 Phase III
5.8 ABT-450/r (Ritonavir) (Company: Abbott Laboratories)
5.8.1 Phase I
5.8.2 Phase II
5.8.3 Phase III
5.9 ABT-267 (Company: Abbott Laboratories)
5.9.1 Phase II
5.9.2 Phase III
5.10 ABT-072/333 (Company: Abbott Laboratories)
5.10.1 Phase I
5.10.2 Phase II
5.10.3 Phase III
5.11 Alisporivir (Company: Novartis)
5.11.1 Phase II
5.11.2 Phase III
© Renub Research Page 6 of 12

7. 6. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II)
6.1 Mericitabine (RG-7128) (Company: Roche)
6.1.1 Phase II
6.2 Danoprevir/r (Ritonavir) (RG7227) (Company: Roche)
6.2.1 Phase I
6.2.2 Phase II
6.3 GS-9256 (Company: Gilead Sciences)
6.3.1 Phase II
6.4 GS-9451 (Company: Gilead Sciences)
6.4.1 Phase II
6.5 MK-5172 (Company: Merck)
6.5.1 Phase I
6.5.2 Phase II
6.6 Sovaprevir (ACH-1625) (Company: Achillion)
6.6.1 Phase II
6.7 IDX-320 (Company: Idenix)
6.7.1 Phase I
6.8 MK-8742 (Company: Merck)
6.8.1 Phase I
6.8.2 Phase II
6.9 ACH-3102 (Company: Achillion Pharmaceuticals, Inc)
6.9.1 Phase I
6.9.2 Phase II
© Renub Research Page 7 of 12

8. 6.10 IDX-719 (Company: Idenix)
6.10.1 Phase I
6.10.2 Phase II
6.11 PPI-668 (Company: Presidio Pharmaceuticals)
6.11.1 Phase I
6.12 Setrobuvir (ANA-598) (Company: Roche)
6.12.1 Phase I
6.12.2 Phase II
6.13 VX-222 (Company: Vertex Pharmaceuticals)
6.13.1 Phase I
6.13.2 Phase II
6.14 GS-9669 (Company: Gilead Sciences )
6.14.1 Phase I
6.14.2 Phase II
6.15 GS-9190 (Tegobuvir) (Company: Gilead Sciences)
6.15.1 Phase II
6.16 BMS-791325 (Company: Bristol-Myers Squibb)
6.16.1 Phase II
7. Hepatitis C - Pipeline Drugs Sales Forecast
7.1 Simeprevir (TMC 435) Sales Forecast
7.2 Faldaprevir (BI 201335) (Boerhinger Ingelheim) Sales Forecast
7.3 Asunaprevir (BMS-650032) Sales Forecast
7.4 Sofosbuvir (PSI-7977 or GS-7977) Sales Forecast
7.5 Daclatasvir (BMS-790052) Sales Forecast
© Renub Research Page 8 of 12

9. 7.6 ABT-450/r (Ritonavir) Sales Forecast
7.7 ABT-072/333 Sales Forecast
7.8 Alisporivir Sales Forecast
7.9 Mericitabine (RG-7128) Sales Forecast
7.10 Danoprevir (RG7227) Sales Forecast
7.11 GS-9256 Sales Forecast
7.12 Setrobuvir (ANA-598) Sales Forecast
7.13 VX-222 Sales Forecast
7.14 GS-9190 (Tegobuvir) Sales Forecast
7.15 BMS-791325 Sales Forecast
© Renub Research Page 9 of 12

10. Order Form
Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact
Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780
Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to
info@renub.com
Format
Report Title: Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline
Drugs Sales & Forecast - Worldwide
Single User
(Email from Publisher)
Hard Copy
(Mail Delivery)
CD – Rom
(Mail Delivery)
Global Site License
(Multiple User License)
US$ 1,290 US$ 1,440 US$ 1,390 US$ 2,090
For ordering this report: Three easy ways to place your order:
1) Order online by Credit Card (Visa, MasterCard, etc.):
http://www.renub.com/report/hepatitis-c-market-forecast-hcv-drugs-clinical-trials-hepatitis-
c-pipeline-drugs-sales-forecast---worldwide-118
2) Order by Wire Transfer:
http://www.renub.com/report/wiretransfer.aspx?id=118&pid=1457
To pay by Wire Transfer, please, fill in your contact details in the form below:
© Renub Research Page 10 of 12

11. Bank Details
Account Name: Renub Research
A/C No.: 109102000023296
Name of Bank: IDBI Bank Ltd.
Swift Code: IBKLINBB010
Bank Address: 4th
Floor
Indian Red Cross Building
1 Red Cross Road
Opposite Parliament Street
New Delhi – 110001
India
Contact Information
First Name: Last Name:
Email:
Job Title:
Company:
Address:
City:
Postal/Zip Code:
Country:
Phone:
Mobile:
Fax:
Report Format:
Your message:
© Renub Research Page 11 of 12

12. 3) Order by Check
Please post the check accompanied by this form, to:
Company Address: Renub Research
1st
floor,
C-86, Sector -10,
Noida - 201301
Uttar Pradesh
India
Phone: +91-120-421-9822, 424-9780
For free Sample copy report or to view any of our sample work please contact us at
info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA)
Follow Us
Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090
LinkedIn: http://www.linkedin.com/company/renub-research
Twitter: http://twitter.com/RenubResearch
© Renub Research Page 12 of 12